



# Adult Respiratory Syncytial Virus (RSV) Session

**Camille Kotton, MD**

**Chair, Adult RSV Work Group**

Advisory Committee on Immunization Practices (ACIP)

February 23, 2023

# Adult RSV Work Group Membership

## ACIP Voting Members

Camille Kotton (Chair)

Keipp Talbot

Sarah Long

## Ex Officio Members

Rachel Zhang (FDA)

Judy Beeler (FDA)

Nicholas Geagan (FDA)

Nadine Peart (FDA)

Sonnie Kim (NIH/NIAID)

Jeffrey Kelman (CMS)

Valerie Marshal (OIDP)

## CDC Lead

Michael Melgar

## Consultants

Robert Atmar (Baylor College of Medicine)

Helen Chu (University of Washington)

Marie Griffin (Vanderbilt University Medical Center)

Cynthia Lucero-Obusan (Veterans Health Administration)

Tracy Ruckwardt (NIH/NIAID)

## Liaisons

Kenneth Schmader (AGS)

Michael Hogue (APhA)

Shmuel Shoham (ACP)

Katherine Williams (APTR)

Gretchen LaSalle (AAFP)

Ruth Lynfield (NFID)

April Killikelly (NACI, PHAC)

Jennifer Heath (AIM)

Winnie Su (NACI, PHAC)

# CDC Contributors

## Coronavirus and Other Respiratory Viruses Division

Fiona Havers

Meredith McMorro

Diya Surie

Jennifer DeCuir

Lauren Roper

Mila Prill

Amanda Payne

Natalie Thornburg

Melissa Coughlin

Jefferson Jones

Katherine Fleming-Dutra

Ismael Ortega Sanchez

## Immunization Safety Office

Anne Hause

David Shay

Christine Olson

## Immunization Services Division

Neil Murthy

Patricia Wodi

Debra Blog

Andrew Leidner

Jamison Pike

# Recap of RSV session, October 2022

- Manufacturer safety and efficacy presentation by GSK regarding adjuvanted candidate RSV vaccine for older adults: RSVpreF3
- Manufacturer safety and efficacy presentation by Pfizer regarding bivalent candidate RSV vaccine for older adults: RSVpreF
- Work group interim considerations regarding novel RSV vaccines for older adults

# Recent work group discussion

- Cost effectiveness of RSV vaccination among U.S. older adults
- GRADE and Evidence to Recommendations for GSK adjuvanted RSVpreF3
- GRADE and Evidence to Recommendations for Pfizer bivalent RSVpreF
- CDC vaccine safety surveillance systems

# Recent work group discussion

- Possible policy recommendations\* for RSV vaccination of U.S. older adults
  - Should RSV vaccines be recommended for U.S. adults aged  $\geq 65$  years?
  - Should RSV vaccines be recommended for U.S. adults aged  $\geq 60$  years?

\*FDA has not yet completed review of safety and efficacy data for the GSK adjuvanted RSVpreF3 vaccine and the Pfizer bivalent RSVpreF vaccine. ACIP recommendations would be made only if the vaccines are approved and licensed by FDA.

# Agenda: Thursday February 23, 2023

- Cost effectiveness of RSV vaccination among U.S. older adults  
Dr. David Hutton  
(U. Michigan)
- Comparison of RSV vaccination economic analyses performed by U. Michigan/CDC, GSK, and Pfizer  
Dr. Ismael Ortega Sanchez  
(CDC)
- Evidence to Recommendations framework for GSK and Pfizer candidate vaccines  
Dr. Michael Melgar (CDC)
- Discussion of vaccine policy options  
Dr. Michael Melgar (CDC)

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

